Results 71 to 80 of about 10,893 (204)
Assessing Risk Thresholds in Controlled Human Infection Models (CHIM)
ABSTRACT Controlled Human Infection Models (CHIMs) are a type of clinical trial involving deliberately exposing human volunteers to an infectious agent. Compared to studies of natural infection, CHIMs offers distinctive benefits, from the ability to study presymptomatic infection to a direct assessment of the efficacy of vaccines and therapeutics in a ...
Alexa Nord‐Bronzyk +4 more
wiley +1 more source
A low‐cost, portable point‐of‐care platform for rapid Mpox detection using loop‐mediated isothermal amplification is reported. The device integrates fluorescence readout and mobile monitoring. A machine‐learning model analyzes temperature data and correlates thermal changes with DNA concentration, enabling sensitive and reliable molecular diagnosis in ...
Nazente Atceken +4 more
wiley +1 more source
Repurpose an FDA‐Approved Antibody Using DARPin‐Scaffolded Bridge Protein
The cell line and scalable upstream/downstream process development needed for every new monoclonal antibody are both highly expensive and time‐consuming, significantly increasing the cost of new antibody therapeutics. By contrast, the production of many synthetic binders can be accomplished rapidly and with lower production costs.
Michael Woolley +4 more
wiley +1 more source
Strategies for the Modification of Vaccinia Virus towards a Better Vaccine Vector
Vaccinia virus (VACV) confers cross-protective immunity against variola virus, the causative agent of smallpox, and has therefore been extensively exploited as a preventive vaccine.
Hao Sun, Xinwen Chen, Yun Wang
doaj +1 more source
ABSTRACT Background Mpox has emerged as a re‐emerging zoonotic disease of global public health concern, particularly affecting regions with limited awareness and preparedness. University students represent a critical population for disease prevention due to their mobility, social interaction, and role as future professionals.
Esubalew Muluneh Aligaz +3 more
wiley +1 more source
Report of the World Health Organization (WHO) Biosafety Inspection Team of the Variola Virus Maximum Containment Laboratories to the Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America, 8-12 May 2017 [PDF]
The WHO team of international experts carried out a biosafety inspection at one of the two WHO- authorized variola virus (causative agent of smallpox) repositories: CDC*, in May 2017 in accordance with World Health Assembly resolution WHA60.1 (2007 ...
core
Variola virus infection in Vero E6 cells at different MOI at 24 hours post infection.
Cell images were collected at 5X magnification with 9 fields per well. Variola virus (Solaimen) was titrated at different MOI concentrations. Wells with uninfected control cells were included on each plate to be used for gating purposes during image ...
Victoria Olson (210647) +5 more
core +1 more source
Monkeypox Virus: Lessons Learnt
The world has been facing a back-to-back hit to life after widespread of viruses since the time of COVID-19. The pandemic had a devastating effect and created history in mankind, but that was not enough for the time.
Sunanda Kulshrestha +2 more
core +1 more source
Misinformation and women's health: Rebuilding trust in evidence‐based care
International Journal of Gynecology &Obstetrics, Volume 173, Issue 3, Page 1632-1633, June 2026.
Zainab Al‐Jawahiri
wiley +1 more source
ABSTRACT Background With the re‐emergence of monkeypox (Mpox), it is vital for communities to assess and effectively respond to emerging outbreaks. This paper aims to review the potential of clade I Mpox to result in a widespread outbreak by assessing genetically enhanced virulence, transmission, and clinical manifestations.
Md. Ashrafur Rahman +5 more
wiley +1 more source

